Korean J Clin Microbiol.  2010 Dec;13(4):169-172. 10.5145/KJCM.2010.13.4.169.

Prevalence of Metallo-beta-lactamases in Imipenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii

• Ryoo NH
• Ha JS
• Jeon DS
• Kim JR

• KMID: 1461612
• DOI: http://doi.org/10.5145/KJCM.2010.13.4.169

Abstract

BACKGROUND
Metallo-beta-lactamases (MBLs) have been reported in gram negative bacilli and are becoming increasingly important clinically because the enzymes hydrolyse almost all beta-lactams, including carbapenems. Thus, the present study was conducted to determine the prevalence of MBL types in imipenem-nonsusceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolated from a tertiary teaching hospital.
METHODS
Imipenem-nonsusceptible strains, 128 P. aeruginosa and 93 A. baumannii, were collected from clinical specimens. Identification and susceptibility tests were determined by Vitek GNI and GNS cards. MBL production was determined by modified Hodge test and imipenem-EDTA synergy test. Multiplex PCR amplification of MBL genes including blaIMP-1, blaVIM-1 and blaVIM-2 were performed.
RESULTS
Thirty-one P. aeruginosa (24.2%) isolates and 3 A. baumannii (3.2%) were found to be MBL producers. In P. aeruginosa, 20 (15.6%) and 11 (8.6%) isolates were positive for blaIMP-1 and blaVIM-2, respectively whereas 1 (1.0%) and 2 (2.2%) isolates in A. baumannii, respectively.
CONCLUSION
IMP-1 is more prevalent MBL type than VIM-2 among imipenem-nonsusceptible P. aeruginosa unlike in other studies. Larger numbers of isolates and sequential studies are strongly recommended for the useful evaluation and monitoring of MBL production in the hospital setting to infection-control.

Keyword

Multidrug resistance; Pseudomonas aeruginosa; Acinetobacter baumannii; Metallo-beta-lactamase (MBL); IMP-1; VIM-2

MeSH Terms

Acinetobacter
Acinetobacter baumannii
beta-Lactams
Carbapenems
Drug Resistance, Multiple
Multiplex Polymerase Chain Reaction
Prevalence
Pseudomonas
Pseudomonas aeruginosa
Carbapenems
beta-Lactams

Reference

1. Jacoby GA and Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991; 35:1697–704.

2. Nordmann P and Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect. 2002; 8:321–31.

3. Queenan AM and Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007; 20:440–58.

4. Cornaglia G, Akova M, Amicosante G, Cantón R, Cauda R, Docquier JD, et al. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents. 2007; 29:380–8.

5. Walther-Rasmussen J and H⊘iby N. OXA-type carbapenemases. J Antimicrob Chemother. 2006; 57:373–83.

6. Lee H, Kim CK, Lee J, Lee SH, Ahn JY, Hong SG, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2005 and 2006. Korean J Clin Microbiol. 2007; 10:59–69.

7. Hong SG, Lee J, Yong D, Kim EC, Jeong SH, Park YJ, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea. Korean J Clin Microbiol. 2004; 7:171–7.

8. Lee K, Yong D, Yum JH, Lim YS, Bolmström A, Qwärnström A, et al. Evaluation of E test MBL for detection of bla_IMP-1 and bla_VIM-2 allele-positive clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2005; 43:942–4.

9. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000; 44:891–7.

10. Lee K, Ha GY, Shin BM, Kim JJ, Kang JO, Jang SJ, et al. Metallo-beta-lactamase-producing gram-negative bacilli in Korean nationwide surveillance of antimicrobial resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis. 2004; 50:51–8.

11. Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM, et al. bla_VIM-2 cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother. 2002; 46:1053–8.

12. Thomson JM and Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol. 2005; 8:518–24.

13. Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, et al. Prevalence of Ambler class A and D beta-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother. 2005; 56:122–7.

14. Yoon WS, Lee BY, Bae IK, Kwon SB, Jeong SH, Jeong TJ, et al. Prevalence of imipenem-resistant Pseudomonas aeruginosa isolates and mechanisms of resistance. Korean J Clin Microbiol. 2005; 8:26–33.

15. Nho SO, Jin JS, Kim JW, Oh JY, Kim J, Lee YC, et al. Dissemination of the bla_IMP-1 and bla_VIM-2 metallo-beta-lactamase genes among genetically unrelated Pseudomonas aeruginosa isolates in a South Korean hospital. Int J Antimicrob Agents. 2008; 31:586–8.

16. Ryoo NH, Lee K, Lim JB, Lee YH, Bae IK, Jeong SH. Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-beta-lactamase in a Korean hospital. Diagn Microbiol Infect Dis. 2009; 63:115–7.

17. Oh EJ, Lee S, Park YJ, Park JJ, Park K, Kim SI, et al. Prevalence of metallo-beta-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii in a Korean university hospital and comparison of screening methods for detecting metallo-beta-lactamase. J Microbiol Methods. 2003; 54:411–8.

18. Kim IS, Lee NY, Ki CS, Oh WS, Peck KR, Song JH. Increasing prevalence of imipenem-resistant Pseudomonas aeruginosa and molecular typing of metallo-beta-lactamase producers in a Korean hospital. Microb Drug Resist. 2005; 11:355–9.